Pharmacologic treatments for pulmonary hypertension: Exploring pharmacogenomics

Julio D. Duarte, Rebekah L. Hanson, Roberto F. Machado

Research output: Contribution to journalReview article

23 Scopus citations

Abstract

Pulmonary hypertension (PH) is a disease with multiple etiologies and is categorized into five broad groups. Of these groups, pulmonary arterial hypertension (PAH) is the most studied and, therefore, all of the currently available drug classes (prostacyclin analogs, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors) were developed to treat PAH. Thus, limited treatment data exist for the less-studied non-PAH forms of PH. Pharmacogenomics can be a tool to better understand the pathways involved in PH, as well as to improve personalization of therapy. However, little pharmacogenomic research has been carried out on this disease. New treatments for PH are on the horizon, deriving from both repurposed currently available drugs and novel therapeutics.

Original languageEnglish (US)
Pages (from-to)335-349
Number of pages15
JournalFuture Cardiology
Volume9
Issue number3
DOIs
StatePublished - May 1 2013
Externally publishedYes

Keywords

  • endothelin receptor antagonist
  • pharmacogenetics
  • pharmacogenomics
  • phosphodiesterase type 5 inhibitor
  • prostacyclin analog
  • pulmonary hypertension

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Pharmacologic treatments for pulmonary hypertension: Exploring pharmacogenomics'. Together they form a unique fingerprint.

  • Cite this